As the market demand for RNA therapeutics such as siRNA and sgRNA is anticipated to grow substantially over the next decade, there is a need for scalable, cost-effective, and sustainable manufacturing solutions.
Chemoenzymatic ligation is a promising approach for siRNA and sgRNA manufacturing, offering enhanced purity, increased yield, and reduced environmental impact. This innovative technology provides an optimal solution to meet the anticipated surge in demand for these drugs over the coming decade.
At TIDES USA 2025, our CTO, David Butler presented the latest advancements in Hongene’s chemoenzymatic ligation platform for oligonucleotides synthesis and provided strategic insights that will help researchers and companies navigate drug development process using the ligation technology.
